{"entity":{"id":"k36-therapeutics","kind":"company","name":"K36 Therapeutics","aka":[],"tldr":"K36 Therapeutics makes pills that block an enzyme called NSD2 (also known as MMSET), which is overactive in about one in five multiple myeloma cases because of a chromosome swap. It is also testing the approach in prostate cancer.","summary":"K36 Therapeutics is a Cambridge, Massachusetts clinical-stage company and the first to target the histone methyltransferase NSD2 (MMSET/WHSC1). Gintemetostat (KTX-1001) is a first-in-class, oral, selective catalytic NSD2 inhibitor in the K36-MMSET-001 trial in relapsed or refractory multiple myeloma with the t(4;14) translocation; the company reports target engagement, an encouraging safety profile and clinical activity in heavily pretreated patients, with expansion cohorts combining it with carfilzomib, mezigdomide or pomalidomide. KTX-2001, a second oral NSD2 inhibitor, is in the K36-STRIKE-001 trial in metastatic castration-resistant prostate cancer alone and with darolutamide. K36 launched in December 2021 with a 30 million US dollar Series A co-led by F-Prime Capital and Atlas Venture, and raised a 70 million US dollar Series B in June 2023 led by Nextech Invest with Bristol Myers Squibb participating.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.k36tx.com/"},{"label":"Series A press release (PR Newswire)","url":"https://www.prnewswire.com/news-releases/k36-therapeutics-launches-with-30-million-series-a-financing-from-f-prime-capital-and-atlas-venture-with-eight-roads-ventures-301440553.html"},{"label":"Series B press release (PR Newswire)","url":"https://www.prnewswire.com/news-releases/k36-therapeutics-announces-70-million-series-b-financing-to-fund-clinical-proof-of-concept-of-ktx-1001-first-in-class-inhibitor-of-mmset-for-treatment-of-multiple-myeloma-patients-with-genetic-translocation-414-301865147.html"}],"tags":[],"related":[],"cancers":["multiple-myeloma","prostate"],"sections":["epigenetics","targeted-therapy"],"technologies":["epigenetic-drugs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No SEC Form D filings were found under the company name. Founding year not sourced."],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://www.k36tx.com/","stage":"startup","investors":["f-prime-capital","atlas-venture"],"funding":[{"round":"Series A","year":2021,"amountUsd":30000000,"source":"https://www.prnewswire.com/news-releases/k36-therapeutics-launches-with-30-million-series-a-financing-from-f-prime-capital-and-atlas-venture-with-eight-roads-ventures-301440553.html","note":"Co-led by F-Prime Capital and Atlas Venture with Eight Roads Ventures"},{"round":"Series B","year":2023,"amountUsd":70000000,"source":"https://www.prnewswire.com/news-releases/k36-therapeutics-announces-70-million-series-b-financing-to-fund-clinical-proof-of-concept-of-ktx-1001-first-in-class-inhibitor-of-mmset-for-treatment-of-multiple-myeloma-patients-with-genetic-translocation-414-301865147.html","note":"Led by Nextech Invest with participation from Bristol Myers Squibb and existing investors"}]},"route":"/companies/k36-therapeutics/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"epigenetics","kind":"section","name":"Epigenetic & Transcriptional Therapy","route":"/fronts/epigenetics/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/"}],"company":[{"id":"atlas-venture","kind":"company","name":"Atlas Venture","route":"/companies/atlas-venture/"},{"id":"f-prime-capital","kind":"company","name":"F-Prime Capital","route":"/companies/f-prime-capital/"}],"roadmap":[{"id":"epigenetics-roadmap","kind":"roadmap","name":"Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome","route":"/roadmaps/epigenetics-roadmap/"}]}}